Magnetic resonance imaging (MRI) contrast agents for tumor diagnosis

Journal of Healthcare Engineering

Volumn 4, Issue 1, 2013, Pages 23-46

  Cheng, Weiren ^a,b   Ping, Yuan ^a   Zhang, Yong ^b   Chuang, Kai Hsiang ^c   Liu, Ye ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c AGENCY FOR SCIENCE   (Singapore)

Author keywords

Diagnosis; Magnetic resonance imaging (MRI); Magnetic resonance imaging (MRI) contrast agent; Metabolism; Tumor

Indexed keywords

MAGNETIC RESONANCE IMAGING; METABOLISM; MOLECULAR WEIGHT; PHYSIOLOGY; SUPERPARAMAGNETISM; TUMORS;

LONGITUDINAL RELAXATION TIME; LOW MOLECULAR WEIGHT; MAGNETIC RESONANCE IMAGING (MRI); MAGNETIC RESONANCE IMAGING CONTRAST AGENTS; MRI CONTRAST AGENTS; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; SUPERPARAMAGNETIC PARTICLES; TRANSVERSE RELAXATION TIME;

DIAGNOSIS;

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM;

HUMAN; IMAGE ENHANCEMENT; METHODOLOGY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW;

CONTRAST MEDIA; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; NEOPLASMS;

MLCS; MLOWN;

EID: 84874872846     PISSN: 20402295     EISSN: 20402309     Source Type: Journal    
DOI: 10.1260/2040-2295.4.1.23     Document Type: Review

References (170)

1. Brindle K. New approaches for imaging tumour responses to treatment. Nature Reviews Cancer, 2008, 8:94-107.
2. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature, 2008, 452:580-589.
3. Aime S, Castelli DD, Crich SG, Gianolio E, Terreno E. Pushing the Sensitivity Envelope of Lanthanide-Based Magnetic Resonance Imaging (MRI) Contrast Agents for Molecular Imaging Applications. Accounts of Chemical Research, 2009, 42:822-831.
4. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications. Chemical Reviews, 1999, 99:2293-2352.
5. Lin WB, Hyeon T, Lanza GM, Zhang MQ, Meade TJ. Magnetic Nanoparticles for Early Detection of Cancer by Magnetic Resonance Imaging. Mrs Bulletin, 2009, 34:441-448.
6. Villaraza AJL, Bumb A, Brechbiel MW. Macromolecules, Dendrimers, and Nanomaterials in Magnetic Resonance Imaging: The Interplay between Size, Function, and Pharmacokinetics. Chemical Reviews, 2010, 110:2921-2959.
7. Damadian RV. Tumor Detection by Nuclear Magnetic Resonance. Science, 1971, 171:1151-1153.
8. Pettersson H, Eliasson J, Egund N, Rooser B, Willen H, Rydholm A, Berg NO, Holtas S. Gadolinium-DTPA enhancement of soft tissue tumors in magnetic resonance imaging - Preliminary clinical experience in five patients. Skeletal Radiology, 1988, 17:319-323.
9. Crisci R, Di Cesare E, Lupattelli L, Coloni GF. MR study of N2 disease in lung cancer: Contrast-enhanced method using gadolinium-DTPA. European Journal of Cardio-thoracic Surgery, 1997, 11:214-217.
10. Hawnaur JM, Johnson RJ, Read G, Isherwood I. Magnetic resonance imaging with Gadolinium-DTPA for assessment of bladder carcinoma and its response to treatment. Clinical Radiology, 1993, 47:302-310.
11. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magnetic resonance in medical sciences, 2007, 6:43-52.
12. Vander Elst L, Maton F, Laurent S, Seghi F, Chapelle F, Muller RN. A multinuclear MR study of Gd-EOB-DTPA: Comprehensive preclinical characterization of an organ specific MRI contrast agent. Magnetic Resonance in Medicine, 1997, 38:604-614.
13. Shimada K, Isoda H, Hirokawa Y, Arizono S, Shibata T, Togashi K. Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. European Radiology, 2010, 20:2690-2698.
14. Clement O, Muhler A, Vexler VS, Kuwatsuru R, Berthezene Y, Rosenau W, Brasch RC. Comparison of Gd-Eob-Dtpa and Gd-Dtpa for Contrast-Enhanced Mr-Imaging of Liver-Tumors. Journal of Magnetic Resonance Imaging, 1993, 3:71-77.
15. Tyeklar Z, Dunham SU, Midelfort K, Scott DM, Sajiki H, Ong K, Lauffer RB, Caravan P, McMurry TJ. Structural, kinetic, and thermodynamic characterization of the interconverting isomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorganic Chemistry, 2007, 46:6621-6631.
16. Tyeklar Z, Dunham SU, Midelfort K, Scott DM, Sajiki H, Ong K, Lauffer RB, Caravan P, McMurry TJ. Structural, kinetic, and thermodynamic characterization of the interconverting isomers of MS-325, a gadolinium(lll)-based magnetic resonance angiography contrast agent. Inorganic Chemistry, 2007, 46:6621-6631.
17. Caravan P, Cloutier NJ, Greenfield MT, McDermid SA, Dunham SU, Bulte JWM, Amedio J, Looby RJ, Supkowski RM, Horrocks J, McMurry TJ, Lauffer RB. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. Journal of the American Chemical Society, 2002, 124:3152-3162.
18. Caravan P, Parigi G, Chasse JM, Cloutier NJ, Ellison JJ, Lauffer RB, Luchinat C, McDermid SA, Spiller M, McMurry TJ. Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorganic Chemistry, 2007, 46:6632-6639.
19. Turetschek K, Floyd E, Helbich T, Roberts TPL, Shames DM, Wendland MF, Carter WO, Brasch RC. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. Journal of Magnetic Resonance Imaging, 2001, 14:237-242.
20. Chen C, Cohen JS, Myers CE, Sohn M. Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging. FEBS Letters, 1984, 168:70-74.
21. Galindev O, Dalantai M, Ahn WS, Shim YK. Gadolinium complexes of chlorin derivatives applicable for MRI contrast agents and PDT. Journal of Porphyrins and Phthalocyanines, 2009, 13:823-831.
22. Sessler JL, Mody TD, Hemmi GW, Lynch V, Young SW, Miller RA. Gadolinium(III) texaphyrin: A novel MRI contrast agent. Journal of the American Chemical Society, 1993, 115:10366-10367.
23. Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. Journal of Biological Chemistry, 2006, 281:10691-10697.
24. Richards GM, Mehta MP. Motexafin gadolinium in the treatment of brain metastases. Expert Opinion on Pharmacotherapy, 2007, 8:351-359.
25. Park JA, Lee JJ, Jung JC, Yu DY, Oh C, Ha S, Kim TJ, Chang Y. Gd-DOTA conjugate of RGD as a potential tumor-targeting MRI contrast agent. Chembiochem, 2008, 9:2811-2813.
26. Zhang W, Chen Y, Guo DJ, Huang ZW, Cai L, He L. The synthesis of a d-glucosamine contrast agent, Gd-DTPA-DG, and its application in cancer molecular imaging with MRI. European Journal of Radiology, 2011, 79:369-374.
27. Sukerkar PA, MacRenaris KW, Meade TJ, Burdette JE. A steroid-conjugated magnetic resonance probe enhances contrast in progesterone receptor expressing organs and tumors in vivo. Molecular Pharmaceutics, 2011, 8:1390-1400.
28. Pais A, Gunanathan C, Margalit R, Biton IE, Yosepovich A, Milstein D, Degani H. In Vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer. Cancer Research, 2011, 71:7387-7397.
29. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods in molecular biology, 2010, 624:25-37.
30. Unger EC, Fritz TA, Tilcock C, New TE. Clearance of liposomal gadolinium: in vivo decomplexation. Journal of magnetic resonance imaging, 1991, 1:689-693.
31. Nwe K, Bryant LH, Brechbiel MW. Poly(amidoamine) Dendrimer Based MRI Contrast Agents Exhibiting Enhanced Relaxivities Derived via Metal Preligation Techniques. Bioconjugate Chemistry, 2010, 21:1014-1017.
32. Floyd WC, Klemm PJ, Smiles DE, Kohlgruber AC, Pierre VC, Mynar JL, Frechet JMJ, Raymond KN. Conjugation Effects of Various Linkers on Gd(III) MRI Contrast Agents with Dendrimers: Optimizing the Hydroxypyridinonate (HOPO) Ligands with Nontoxic, Degradable Esteramide (EA) Dendrimers for High Relaxivity. Journal of the American Chemical Society, 2011, 133:2390-2393.
33. Yang JJ, Yang JH, Wei LX, Zurkiya O, Yang W, Li SY, Zou J, Zhou YB, Maniccia ALW, Mao H, Zhao FQ, Malchow R, Zhao SM, Johnson J, Hu XP, Krogstad E, Liu ZR. Rational design of protein-based MRI contrast agents. Journal of the American Chemical Society, 2008, 130:9260-9267.
34. Caravan P. Protein-Targeted Gadolinium-Based Magnetic Resonance Imaging (MRI) Contrast Agents: Design and Mechanism of Action. Accounts of Chemical Research, 2009, 42:851-862.
35. Opsahl LR, Uzgiris EE, Vera DR. Tumor Imaging with A Macromolecular Paramagnetic Contrast Agent - Gadopentetate Dimeglumine-Polylysine. Academic Radiology, 1995, 2:762-767.
36. Yan GP, Liu ML, Li LY. Polyaspartamide gadolinium complexes containing sulfadiazine groups as potential macromolecular MRI contrast agents. Bioconjugate Chemistry, 2005, 16:967-971.
37. Ye FR, Ke TY, Jeong EK, Wang XL, Sung YG, Johnson M, Lu ZR. Noninvasive visualization of in vivo drug delivery of poly(L-glutamic acid) using contrast-enhanced MRI. Molecular Pharmaceutics, 2006, 3:507-515.
38. Sirlin CB, Vera DR, Corbeil JA, Caballero MB, Buxton RB, Mattrey RF. Gadolinium-DTPA-dextran: A macromolecular MR blood pool contrast agent. Academic Radiology, 2004, 11:1361-1369.
39. Helbich TH, Gossman A, Mareski PA, Raduchel B, Roberts TPL, Shames DM, Muhler M, Turetschek K, Brasch RC. A new polysaccharide macromolecular contrast agent for MR imaging: Biodistribution and imaging characteristics. Journal of Magnetic Resonance Imaging, 2000, 11:694-701.
40. Vera DR, Buonocore MH, Wisner ER, Katzberg RW, Stadalnik RC. A Molecular Receptor-Binding Contrast Agent for Magnetic-Resonance-Imaging of the Liver. Academic Radiology, 1995, 2:497-506.
41. Andre JP, Geraldes CFGC, Martins JA, Merbach AE, Prata MIM, Santos AC, de Lima JJP, Toth E. Lanthanide(III) complexes of DOTA-glycoconjugates: A potential new class of lectin-mediated medical imaging agents. Chemistry, 2004, 10:5804-5816.
42. Baia P, Andre JP, Geraldes CFGC, Martins JA, Merbach AE, Toth T. Lanthanide(III) chelates of DTPA bis(amide) glycoconjugates: Potential imaging agents targeted at the asyaloglycoprotein receptor. European Journal of Inorganic Chemistry, 2005, 2110-2119.
43. Laus S, Sour A, Ruloff R, Toth E, Merbach AE. Rotational dynamics account for pH-dependent relaxivities of PAMAM dendrimeric, Gd-based potential MRI contrast agents. Chemistry, 2005, 11:3064-3076.
44. Laus S, Ruloff R, Toth E, Merbach AE. Gd-III complexes with fast water exchange and high thermodynamic stability: Potential building blocks for high-relaxivity MRI contrast agents. Chemistry; 2003, 9:3555-3566.
45. Rudovsky J, Kotek J, Hermann P, Lukes I, Mainero V, Aime S. Synthesis of a bifunctional monophosphinic acid DOTA analogue ligand and its lanthanide(III) complexes. A gadolinium(III) complex endowed with an optimal water exchange rate for MRI applications. Organic & Biomolecular Chemistry, 2005, 3:112-117.
46. Ali MM, Woods M, Caravan P, Opina ACL, Spiller M, Fettinger JC, Sherry AD. Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent. Chemistry, 2008, 14:7250-7258.
47. Sato N, Kobayashi H, Hiraga A, Saga T, Togashi K, Konishi J, Brechbiel MW. Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magnetic Resonance in Medicine, 2001, 46:1169-1173.
48. Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW. Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Research, 2003, 63:271-276.
49. Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Brechbiel MW, Choyke PL. Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase. Bioconjugate Chemistry, 2003, 14:1044-1047.
50. Yordanov AT, Kobayashi H, English SJ, Reijnders K, Milenic D, Krishna MC, Mitchell JB, Brechbiel MW. Gadolinium-labeled dendrimers as biometric nanoprobes to detect vascular permeability. Journal of Materials Chemistry, 2003, 13:1523-1525.
51. Cyran CC, Fu YJ, Raatschen HJ, Rogut V, Chaopathomkul B, Shames DM, Wendland MF, Yeh BM, Brasch RC. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. Journal of Magnetic Resonance Imaging, 2008, 27:581-589.
52. Kojima C, Turkbey B, Ogawa M, Bernardo M, Regino CAS, Bryant LH, Choyke PL, Kono K, Kobayashi H. Dendrimer-based MRI contrast agents: The effects of PEGylation on relaxivity and pharmacokinetics. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7:1001-1008.
53. Luo K, Liu G, She W, Wang Q, Wang G, He B, Ai H, Gong Q, Song B, Gu Z. Gadolinium-labeled peptide dendrimers with controlled structures as potential magnetic resonance imaging contrast agents. Biomaterials, 2011, 32:7951-7960.
54. Nwe K, Milenic DE, Ray GL, Kim YS, Brechbiel MW. Preparation of cystamine core dendrimer and antibody - Dendrimer conjugates for MRI angiography. Molecular Pharmaceutics, 2012, 9:374-381.
55. Kobayashi H, Sato N, Saga T, Nakamoto Y, Ishimori T, Toyama S, Togashi K, Konishi J, Brechbiel MW. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. European Journal of Nuclear Medicine, 2000, 27:1334-1339.
56. Konda SD, Aref M, Brechbiel M, Wiener EC. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: Work in progress. Investigative Radiology, 2000, 35:50-57.
57. Konda SD, Wang S, Brechbiel M, Wiener EC. Biodistribution of a 153Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Investigative Radiology, 2002, 37:199-204.
58. Konda SD, Aref M, Wang S, Brechbiel M, Wiener EC. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magnetic Resonance Materials in Physics, Biology and Medicine, 2001, 12:104-113.
59. Wiener EC, Konda S, Shadron A, Brechbiel M, Gansow O. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Investigative Radiology, 1997, 32:748-754.
60. Boswell CA, Eck PK, Regino CAS, Bernardo M, Wong KJ, Milenic DE, Choyke PL, Brechbiel MW. Synthesis, characterization, and biological evaluation of integrin alphavbeta 3-targeted PAMAM dendrimers. Molecular Pharmaceutics, 2008, 5:527-539.
61. Cheng ZL, Thorek DLJ, Tsourkas A. Gadolinium-Conjugated Dendrimer Nanoclusters as a Tumor- Targeted T-1 Magnetic Resonance Imaging Contrast Agent. Angewandte Chemie International Edition, 2010, 49:346-350.
62. Miyake, Y., Kimura, Y., Ishikawa, S., Tsujita, H., Miura, H., Narazaki, M., Matsuda, T., Tabata, Y., Yano, T., Toshimitsu, A., and Kondo, T. Synthesis and functional evaluation of chiral dendrimertriamine-coordinated Gd complexes as highly sensitive MRI contrast agents. Tetrahedron Letters, 2012, 53(34):4580-4583.
63. Klemm PJ, Floyd WC, Smiles DE, Frãchet JMJ, Raymond KN. Improving T1 and T2 magnetic resonance imaging contrast agents through the conjugation of an esteramide dendrimer to high-water- coordination Gd(III) hydroxypyridinone complexes. Contrast Media and Molecular Imaging, 2012, 7:95-99.
64. Schmiedl U, Ogan MD, Moseley ME, Brasch RC. Comparison of the contrast-enhancing properties of albumin-(Gd-DTPA) and Gd-DTPA at 2.0 T: An experimental study in rats. American Journal of Roentgenology, 1986, 147:1263-1270.
65. Lauffer RB, Brady TJ. Preparation and water relaxation properties of proteins labeled with paramagnetic metal chelates. Magnetic Resonance Imaging, 1985, 3:11-16.
66. Paajanen H, Reisto T, Hemmila I, Komu M, Niemi P, Kormano M. Proton relaxation enhancement of albumin, immunoglobulin G, and fibrinogen labeled with Gd-DTPA. Magnetic Resonance in Medicine, 1990, 13:38-43.
67. Wikstrom MG, Moseley ME, White DL, Dupon JW, Winkelhake JL, Kopplin J, Brasch RC. Contrast- enhanced MRI of tumors. Comparison of Gd-DTPA and a macromolecular agent. Investigative Radiology, 1989, 24:609-615.
68. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, Lu Y, Brasch RC. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media. American Journal of Roentgenology, 1998, 171:941-949.
69. Gossmann A, Okuhata Y, Shames DM, Helbich TH, Roberts TPL, Wendland MF, Huber S, Brasch RC. Prostate cancer tumor grade differentiation with dynamic contrast- enhanced MR imaging in the rat: Comparison of macromolecular and small- molecular contrast media - Preliminary experience. Radiology, 1999, 213:265-272.
70. Van Dijke CF, Brasch RC, Roberts TPL, Weidner N, Mathur A, Shames DM, Mann JS, Demsar F, Lang P, Schwickert HC. Mammary carcinoma model: Correlation of macromolecular contrastenhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology, 1996, 198:813-818.
71. Turetschek K, Huber S, Floyd E, Helbich T, Roberts TPL, Shames DM, Tarlo KS, Wendland MF, Brasch RC. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology, 2001, 218:562-569.
72. Aicher KP, Dupon JW, White DL, Aukerman SL, Moseley ME, Juster R, Rosenau W, Winkelhake JL, Brasch RC. Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha. Cancer Research, 1990, 50:7376-7381.
73. Schwickert HC, Stiskal M, Roberts TPL, Van Dijke CF, Mann J, MÃhler A, Shames DM, Demsar F, Disston A, Brasch RC. Contrast-enhanced MR imaging assessment of tumor capillary permeability: Effect of irradiation on delivery of chemotherapy. Radiology, 1996, 198:893-898.
74. Murad GJA, Walbridge S, Morrison PF, Garmestani K, Degen JW, Brechbiel MW, Oldfield EH, Lonser RR. Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to Pseudomonas exotoxin. Clinical Cancer Research, 2006, 12:3145-3151.
75. Krishnan AS, Neves AA, De Backer MM, Hu DE, Davletov B, Kettunen MI, Brindle KM. Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology, 2008, 246:854-862.
76. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Research, 2003, 63:2723-2727.
77. Shahbazi-Gahrouei D, Rizvi SM, Williams MA, Allen BJ. In vitro studies of gadolinium-DTPA conjugated with monoclonal antibodies as cancer-specific magnetic resonance imaging contrast agents. Australasian Physical and Engineering Sciences in Medicine, 2002, 25:31-38.
78. Shahbazi-Gahrouei D, Williams M, Rizvi S, Allen BJ. In vivo studies of Gd-DTPA-monoclonal antibody and Gd-porphyrins: Potential magnetic resonance imaging contrast agents for melanoma. Journal of Magnetic Resonance Imaging, 2001, 14:169-174.
79. Kuriu Y, Otsuji E, Kin S, Nakase Y, Fukuda KI, Okamoto K, Hagiwara A, Yamagishi H. Monoclonal antibody conjugated to gadolinium as a contrast agent for magnetic resonance imaging of human rectal carcinoma. Journal of Surgical Oncology, 2006, 94:144-148.
80. Curtet C, Tellier C, Bohy J. Selective modification of NMR relaxation time in human colorectal carcinoma by using gadolinium ̇diethylenetriaminepentaacetic acid conjugated with monoclonal antibody 19-9. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83:4277-4281.
81. Curtet C, Bourgoin C, Bohy J, Saccavini JC, Thedrez P, Akoka S, Tellier C, Chatal JF. Gd-25 DTPA- MAb, a potential NMR contrast agent for MRI in the xenografted nude mouse: Preliminary studies. International Journal of Cancer, 1988, 41:126-132.
82. Unger EC, Totty WG, Neufeld DM. Magnetic resonance imaging using gadolinium labeled monoclonal antibody. Investigative Radiology, 1985, 20:693-700.
83. Anderson-Berg WT, Strand M, Lempert TE. Nuclear magnetic resonance and gamma camera tumor imaging using gadolinium-labeled monoclonal antibodies. Journal of Nuclear Medicine, 1986, 27:829-833.
84. Ratzinger G, Agrawal P, Körner W, Lonkai J, Sanders HMHF, Terreno E, Wirth M, Strijkers GJ, Nicolay K, Gabor F. Surface modification of PLGA nanospheres with Gd-DTPA and Gd-DOTA for high-relaxivity MRI contrast agents. Biomaterials, 2010, 31:8716-8723.
85. Shiraishi K, Kawano K, Minowa T, Maitani Y, Yokoyama M. Preparation and in vivo imaging of PEG- poly(L-lysine)-based polymeric micelle MRI contrast agents. Journal of Controlled Release, 2009, 136:14-20.
86. Nakamura E, Makino K, Okano T, Yamamoto T, Yokoyama M. A polymeric micelle MRI contrast agent with changeable relaxivity. Journal of Controlled Release, 2006, 114:325-333.
87. Shiraishi K, Kawano K, Maitani Y, Yokoyama M. Polyion complex micelle MRI contrast agents from poly(ethylene glycol)-b-poly(l-lysine) block copolymers having Gd-DOTA; preparations and their control of T 1-relaxivities and blood circulation characteristics. Journal of Controlled Release, 2010, 148:160-167.
88. Kaida S, Cabral H, Kumagai M, Kishimura A, Terada Y, Sekino M, Aoki I, Nishiyama N, Tani T, Kataoka K. Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model. Cancer Research, 2010, 70:7031-7041.
89. Li X, Qian Y, Liu T, Hu X, Zhang G, You Y, Liu S. Amphiphilic multiarm star block copolymer-based multifunctional unimolecular micelles for cancer targeted drug delivery and MR imaging. Biomaterials, 2011, 32:6595-6605.
90. Liao Z, Wang H, Wang X, Zhao P, Wang S, Su W, Chang J. Multifunctional nanoparticles composed of a poly(dl -lactide-coglycolide) core and a paramagnetic liposome shell for simultaneous magnetic resonance imaging and targeted therapeutics. Advanced Functional Materials, 2011, 21:1179-1186.
91. Liu T, Qian Y, Hu X, Ge Z, Liu S. Mixed polymeric micelles as multifunctional scaffold for combined magnetic resonance imaging contrast enhancement and targeted chemotherapeutic drug delivery. Journal of Materials Chemistry, 2012, 22:5020-5030.
92. 2-cyclodextrin-Based star copolymer covalently conjugated with doxorubicin and DOTA-Gd moieties. Biomaterials, 2012, 33:2521-2531.
93. Bui T, Stevenson J, Hoekman J, Zhang S, Maravilla K, Ho RJY. Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging. PLoS ONE, 2010, 5:1-7.
94. Aime S, Castelli DD, Crich SG, Gianolio E, Terreno E. Pushing the Sensitivity Envelope of Lanthanide-Based Magnetic Resonance Imaging (MRI) Contrast Agents for Molecular Imaging Applications. Accounts of Chemical Research, 2009, 42:822-831.
95. Unger EC, Winokur T, MacDougall P, Rosenblum J, Clair M, Gatenby R, Tilcock C. Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging. Radiology, 1989, 171:81-85.
96. Li W, Su B, Meng S, Ju L, Yan L, Ding Y, Song Y, Zhou W, Li H, Tang L, Zhao Y, Zhou C. RGD- targeted paramagnetic liposomes for early detection of tumor: In vitro and in vivo studies. European Journal of Radiology, 2011, 80:598-606.
97. Korotcov A, Shan L, Meng H, Wang T, Sridhar R, Zhao Y, Liang XJ, Wang PC. A nanocomplex system as targeted contrast agent delivery vehicle for magnetic resonance imaging dynamic contrast enhancement study. Journal of Nanoscience and Nanotechnology, 2010, 10:7545-7549.
98. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). Journal of Magnetic Resonance, 2000, 143:79-87.
99. Lin W, Vivero-Escoto JL, Taylor-Pashow KML, Huxford RC, Della Rocca J, Okoruwa C, An H, Lin W. Multifunctional mesoporous silica nanospheres with cleavable Gd(III) chelates as MRI contrast agents: Synthesis, characterization, target-specificity, and renal clearance. Small, 2011, 7:3519-3528.
100. Shao Y, Tian X, Hu W, Zhang Y, Liu H, He H, Shen Y, Xie F, Li L. The properties of Gd 2O 3- assembled silica nanocomposite targeted nanoprobes and their application in MRI. Biomaterials, 2012, 33:6438-6446.
101. Wu Y, Xu X, Tang Q, Li Y. A new type of silica-coated Gd 2(CO 3) 3:Tb nanoparticle as a bifunctional agent for magnetic resonance imaging and fluorescent imaging. Nanotechnology, 2012, 23.
102. Datta A, Hooker JM, Botta M, Francis MB, Aime S, Raymond KN. High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: Nanosized MRI contrast agents. Journal of the American Chemical Society, 2008, 130:2546-2552.
103. Moriggi L, Cannizzo C, Dumas E, Mayer CR, Ulianov A, Helm L. Gold Nanoparticles Functionalized with Gadolinium Chelates as High-Relaxivity MRI Contrast Agents. Journal of the American Chemical Society, 2009, 131:10828-+.
104. Song Y, Xu XY, MacRenaris KW, Zhang XQ, Mirkin CA, Meade TJ. Multimodal Gadolinium- Enriched DNA-Gold Nanoparticle Conjugates for Cellular Imaging. Angewandte ChemieInternational Edition, 2009, 48:9143-9147.
105. Zhang JF, Fatouros PP, Shu CY, Reid J, Owens LS, Cai T, Gibson HW, Long GL, Corwin FD, Chen ZJ, Dorn HC. High Relaxivity Trimetallic Nitride (Gd3N) Metallofullerene MRI Contrast Agents with Optimized Functionality. Bioconjugate Chemistry, 2010, 21:610-615.
106. Shu CY, Corwin FD, Zhang JF, Chen ZJ, Reid JE, Sun MH, Xu W, Sim JH, Wang CR, Fatouros PP, Esker AR, Gibson HW, Dorn HC. Facile Preparation of a New Gadofullerene-Based Magnetic Resonance Imaging Contrast Agent with High H-1 Relaxivity. Bioconjugate Chemistry, 2009, 20:1186-1193.
107. Wang YXJ, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. European Radiology, 2001, 11:2319-2331.
108. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. Journal of Magnetic Resonance Imaging, 1999, 9:228-232.
109. Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, Petrillo A, Rink D, Neuwelt EA. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. American Journal of Neuroradiology, 2002, 23:510-519.
110. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Advanced Drug Delivery Reviews, 2006, 58:1471-1504.
111. Sun C, Du K, Fang C, Bhattarai N, Veiseh O, Kievit F, Stephen Z, Lee D, Ellenbogen RG, Ratner B, Zhang M. PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo. ACS Nano, 2010, 4:2402-2410.
112. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 2005, 26:3995-4021.
113. Laurent S, Forge D, Port M, Roch A, Robic C, Vander EL, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chemical Review, 2008, 108:2064-2110.
114. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty IB, Bawendi MG, Frangioni JV. Renal clearance of quantum dots. Nature Biotechnology, 2007, 25:1165-1170.
115. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M. Long-circulating iron oxides for MR imaging. Advanced Drug Delivery Reviews, 1995, 16:321-334.
116. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J. Superparamagnetic iron oxide: pharmacokinetics and toxicity. American Journal of Roentgenol, 1989, 152:167-173.
117. Lin WB, Hyeon T, Lanza GM, Zhang MQ, Meade TJ. Magnetic Nanoparticles for Early Detection of Cancer by Magnetic Resonance Imaging. Mrs Bulletin, 2009, 34:441-448.
118. Saini S, Stark DD, Hahn PF, Bousquet JC, Introcasso J, Wittenberg J, Brady TJ, Ferrucci JT, Jr. Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology, 1987, 162:217-222.
119. Saini S, Stark DD, Hahn PF, Bousquet JC, Introcasso J, Wittenberg J, Brady TJ, Ferrucci JT, Jr. Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology, 1987, 162:217-222.
120. Stark DD, Weissleder R, Elizondo G, Hahn PF, Saini S, Todd LE, Wittenberg J, Ferrucci JT. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology, 1988, 168:297-301.
121. Reimer P, Jahnke N, Fiebich M, Schima W, Deckers F, Marx C, Holzknecht N, Saini S. Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxideenhanced MR imaging, and spiral CT-ROC analysis. Radiology, 2000, 217:152-158.
122. Weissleder R, Hahn PF, Stark DD, Elizondo G, Saini S, Todd LE, Wittenberg J, Ferrucci JT. Superparamagnetic Iron-Oxide - Enhanced Detection of Focal Splenic Tumors with Mr Imaging. Radiology, 1988, 169:399-403.
123. Laurent S, Forge D, Port M, Roch A, Robic C, Vander EL, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chemical Reviews, 2008, 108:2064-2110.
124. Neuberger T, Schopf B, Hofmann H, Hofmann M, von Rechenberg B. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. Journal of Magnetism and Magnetic Materials, 2005, 293:483-496.
125. Anzai Y, Piccoli CW, Outwater EK, Stanford W, Bluemke DA, Nurenberg P, Saini S, Maravilla KR, Feldman DE, Schmiedl UP, Brunberg JA, Francis IR, Harms SE, Som PM, Tempany CM. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology, 2003, 228:777-788.
126. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Advanced Drug Delivery Reviews, 2008, 60:1241-1251.
127. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la RJ, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. The New England Journal of Medicine, 2003, 348:2491-2499.
128. Harisinghani MG, Jhaveri KS, Weissleder R, Schima W, Saini S, Hahn PF, Mueller PR. MRI contrast agents for evaluating focal hepatic lesions. Clinical Radiology, 2001, 56:714-725.
129. Harisinghani MG, Saini S, Weissleder R, Halpern EF, Schima W, Rubin DL, Stillman AE, Sica GT, Small WC, Hahn PF. Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood-pool contrast agent Code-7227. Radiology, 1997, 202:687-691.
130. Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Accounts of Chemical Research, 2011, 44:842-852.
131. Teja AS, Koh PY. Synthesis, properties, and applications of magnetic iron oxide nanoparticles. Progress in Crystal Growth and Characterization of Materials, 2009, 55:22-45.
132. Massart R. Preparation of Aqueous Magnetic Liquids in Alkaline and Acidic Media. IEEE Transactions on Magnetics, 1981, 17:1247-1248.
133. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 2005, 26:3995-4021.
134. Sun SH, Zeng H, Robinson DB, Raoux S, Rice PM, Wang SX, Li GX. Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. Journal of the American Chemical Society, 2004, 126:273-279.
135. Lee JH, Huh YM, Jun Y, Seo J, Jang J, Song HT, Kim S, Cho EJ, Yoon HG, Suh JS, Cheon J. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nature Medicine, 2007, 13:95-99.
136. Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Accounts of Chemical Research, 2011, 44:842-852.
137. Laurent S, Forge D, Port M, Roch A, Robic C, Vander EL, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chemical Reviews, 2008, 108:2064-2110.
138. Gupta AK, Wells S. Surface-modified superparamagnetic nanoparticles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE Trans Nanobioscience, 2004, 3:66-73.
139. Gupta AK, Curtis AS. Surface modified superparamagnetic nanoparticles for drug delivery: interaction studies with human fibroblasts in culture. Journal of Materials Science: Materials in Medicine, 2004, 15:493-496.
140. Kohler N, Fryxell GE, Zhang M. A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. Journal of American Chemical Society, 2004, 126:7206-7211.
141. Lee H, Yu MK, Park S, Moon S, Min JJ, Jeong YY, Kang HW, Jon S. Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. Journal of American Chemical Society, 2007, 129:12739-12745.
142. Amstad E, Zurcher S, Mashaghi A, Wong JY, Textor M, Reimhult E. Surface functionalization of single superparamagnetic iron oxide nanoparticles for targeted magnetic resonance imaging. Small, 2009, 5:1334-1342.
143. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, Chin SF, Sherry AD, Boothman DA, Gao J. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Letters, 2006, 6:2427-2430.
144. Lee H, Yu MK, Park S, Moon S, Min JJ, Jeong YY, Kang HW, Jon S. Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. Journal of American Chemical Society, 2007, 129:12739-12745.
145. Amstad E, Zurcher S, Mashaghi A, Wong JY, Textor M, Reimhult E. Surface functionalization of single superparamagnetic iron oxide nanoparticles for targeted magnetic resonance imaging. Small, 2009, 5:1334-1342.
146. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, Chin SF, Sherry AD, Boothman DA, Gao J. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Letters, 2006, 6:2427-2430.
147. Laurent S, Forge D, Port M, Roch A, Robic C, Vander EL, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chemical Reviews, 2008, 108:2064-2110.
148. Lu Y, Yin YD, Mayers BT, Xia YN. Modifying the surface properties of superparamagnetic iron oxide nanoparticles through a sol-gel approach. Nano Letters, 2002, 2:183-186.
149. Kim J, Kim HS, Lee N, Kim T, Kim H, Yu T, Song IC, Moon WK, Hyeon T. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angewandte Chemie Internationl Edition, 2008, 47:8438-8441.
150. Liu Q, Zhang J, Xia W, Gu H. Magnetic field enhanced cell uptake efficiency of magnetic silica mesoporous nanoparticles. Nanoscale, 2012, 4:3415-3421.
151. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Advanced Drug Delivery Reviews, 2008, 60:1241-1251.
152. Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Accounts of Chemical Research, 2011, 44:842-852.
153. Laurent S, Forge D, Port M, Roch A, Robic C, Vander EL, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chemical Reviews, 2008, 108:2064-2110.
154. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nature Biotechnology, 2005, 23:1418-1423.
155. Leimgruber A, Berger C, Cortez-Retamozo V, Etzrodt M, Newton A, Waterman P, Figueiredo JL, Kohler R, Elpek N, Mempel TR, Swirski FK, Nahrendorf M, Weissleder R, Pittet MJ. Behavior of Endogenous Tumor-Associated Macrophages Assessed In Vivo Using a Functionalized Nanoparticle. Neoplasia, 2009, 11:459-U58.
156. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nature Biotechnology, 2005, 23:1418-1423.
157. Tsourkas A, Shinde-Patil VR, Kelly KA, Patel P, Wolley A, Allport JR, Weissleder R. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjugate Chemistry, 2005, 16:576-581.
158. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circulation Research, 2005, 96:327-336.
159. Kelly KA, Nahrendorf M, Yu AM, Reynolds F, Weissleder R. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Molecular Imaging and Biology, 2006, 8:201-207.
160. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation, 2006, 114:1504-1511.
161. Choi H, Choi SR, Zhou R, Kung HF, Chen IW. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Academic Radiology, 2004, 11:996-1004.
162. Chen TJ, Cheng TH, Hung YC, Lin KT, Liu GC, Wang YM. Targeted folic acid-PEG nanoparticles for noninvasive imaging of folate receptor by MRI. Journal of Biomedical Materials Research A, 2008, 87:165-175.
163. Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magnetic Resonance in Medicine, 1998, 40:236-242.
164. Xie J, Chen K, Lee HY, Xu C, Hsu AR, Peng S, Chen X, Sun S. Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. Journal of American Chemical Society, 2008, 130:7542-7543.
165. Lin RY, Dayananda K, Chen TJ, Chen CY, Liu GC, Lin KL, Wang YM. Targeted RGD nanoparticles for highly sensitive in vivo integrin receptor imaging. Contrast Media & Molecular Imaging, 2012, 7:7-18.
166. McIntyre DJO, Madhu B, Lee SH, Griffiths JR. Magnetic Resonance Spectroscopy of Cancer Metabolism and Response to Therapy. Radiation Research, 2012, 177:398-435.
167. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nature Medicine, 2001, 7:1241-1244.
168. Neves AA, Krishnan AS, Kettunen MI, Hu DE, de Backer MM, Davletov B, Brindle KM. A paramagnetic nanoprobe to detect tumor cell death using magnetic resonance imaging. Nano Letters, 2007, 7:1419-1423.
169. De Leon-Rodriguez LM, Lubag AJ, Malloy CR, Martinez GV, Gillies RJ, Sherry AD. Responsive MRI agents for sensing metabolism in vivo. Accounts of Chemical Research, 2009, 42:948-957.
170. Iwaki S, Hanaoka K, Piao W, Komatsu T, Ueno T, Terai T, Nagano T. Development of hypoxia- sensitive Gd3+-based MRI contrast agents. Bioorganic & Medicinal Chemistry Letters, 2012, 22:2798-2802.